

WESTERN SYDNEY UNIVERSITY TO UNDERTAKE CLINICAL TRIALS

Cann Global Limited (ASX:CGB) (“Cann Global” or the “Company”) is pleased to announce it has signed a binding agreement with Western Sydney University’s NICM Health Research Institute to design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia to evaluate the efficacy of a unique strain of medicinal cannabis to slow the progression of Multiple Sclerosis (MS).

The proposed human clinical trials follow the successful research previously undertaken for Cann Global at the Technion in Israel headed by Dr Dedi Meiri. As announced to the market on 15 June 2020, the Technion research identified a chemovar in a unique cannabis strain that both in vitro and in vivo (in mice trials) stopped the progression of MS, and in some cases significantly reversed the damage caused by MS. (ASX Release) https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02244502-6A982512?access_token=83ff96335c2d45a094df02a206a39ff4.

Cann Global announced at the recent half year results on 26 February that human clinical trials for this research would be continued in Australia where clinical data and results are recognised worldwide due to the high standard of research. The Australian government also offers significant support to Australian Companies for Australian based medical research.

NICM Health Research Institute is Australia’s leader in integrative and complementary medicine research and policy. Seed funded by the Commonwealth Government and NSW Government, the Institute plays a key national role in ensuring Australians have access to reliable evidence on complementary medicines and treatments in wide use. NICM Health Research Institute is globally recognised for its world-class research and innovations in integrative and complementary medicine.

NICM Health Research Institute has agreed to design a clinical trial protocol in consultation with Cann Global Limited and clinical specialists in the field. The clinical trial protocol is expected to include:

- a background scientific literature review
- trial design
- establishment of the proposed research team
- target population
- definition of primary and secondary outcomes
- calculation of study power and participant numbers
- inclusion and exclusion criteria, randomisation, study procedures, recruitment methods and statistical analysis plan.

Cann Global will update the market with the expected timetable for implementation of the clinical trials once the protocol has been designed.

In addition to implementing the formal clinical trials, Cann Global intends to make this unique chemovar widely available to patients in Australia during this calendar year via prescription under the special access scheme.

ASX ANNOUNCEMENT

06 APRIL 2021



ABOUT CANN GLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on +61 (0)2 8379 1832, or via email at investorrelations@cannglobal.com.au

For personal use only

Level 21, 133 Castlereagh Street,
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

investorrelations@cannglobal.com.au

www.cannglobal.com.au